Study of Platelet-rich Plasma in Treating Patients With Tibiofemoral Cartilage Degeneration
NCT ID: NCT01418755
Last Updated: 2011-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2009-01-31
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Platelet Rich Plasma Injection for Knee Pain
NCT01747018
Clinical and Comparative Evaluation of the Treatment Results of Arthroscopic Reconstruction of Cartilage Defects in the Knee Joint With the Use of Autogenous Cartilage Graft With PRP GF (Platelet-rich Plasma With Growth Factors)
NCT05328674
Treatment of Refractory Patellar Tendinopathy With Mesenquimal Trunk Cells. Comparative Study With PRP.
NCT03454737
Use of Fresh Platelet Rich Plasma With Concentrated Leukocytes or Fresh Platelet Rich Plasma Without Concentrated Leukocytes in the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial
NCT04187183
Evaluation of Treatment of Osteoarthritis of the Knee in the Form of Chondromalacia of the Articular Cartilage Treated in the Arthroscopic Technique With the Use of:Autogenous Transplantation of Fragmented Adipose Tissue,PRP GF,Mesenchymal Cells,Hyaluronic Acid-low Molecular Weight and Cross-linked
NCT07110402
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
platelet rich plasma injection
Fifty consecutive and strictly selected patients, affected by Grade II or III chondromalacia, underwent one year treatment (9 injections) with autologous PRP in a liquid form with 2,0 to 2,5-fold platelets concentration. Outcome measures included the Lysholm, Tegner, IKDC, and Cincinnati scores. Magnetic resonance imaging was used to evaluate cartilage thickness and degree of degeneration.
platelet rich plasma injection
The approximate 2.0 to 2.5-fold platelet concentration (taking into consideration the mean human blood platelet count of 200 000 /μl) was achieved in all specimens. Mean platelet concentration in PRP was 459 000 /μl (range, 407 000 /μl to 513 000 /μl).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
platelet rich plasma injection
The approximate 2.0 to 2.5-fold platelet concentration (taking into consideration the mean human blood platelet count of 200 000 /μl) was achieved in all specimens. Mean platelet concentration in PRP was 459 000 /μl (range, 407 000 /μl to 513 000 /μl).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* patellofemoral chondral damage;
* associated intraarticular lesions confirmed during arthroscopy (menisci, ligaments, osteochondral defects);
* associated extraarticular lesions confirmed by magnetic resonance imaging (ligaments, tendons, bursae);
* lower limb axial deviation confirmed by whole leg weight-bearing radiograph; knee trauma in patients history;
* body mass index (BMI) higher than 35;
* hyaluronic acid intraarticular injection 6 months prior the arthroscopy and up to last follow-up control;
* steroids intraarticular injection 3 months prior the arthroscopy and up to last follow-up control;
* symptomatic slow acting drugs for osteoarthritis (SYSADOA) and/or non-steroidal anti-inflammatory drugs (NSAID) administration during the PRP treatment;
* systemic autoimmune rheumatic and/or polyarticular disease; gout, pseudogout and hyperuricaemia.
31 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Komzak Martin, M.D.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Komzak Martin, M.D.
Hart Radek, M.D., Ph.D., FRS, prof.; Orthopaedic- Traumatologic department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Radek Hart, prof, M.D.
Role: PRINCIPAL_INVESTIGATOR
Hospital Znojmo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Znojmo
Znojmo, , Czechia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
web site of Investigator´s institution
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NT12057
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.